Cortlandt Manor, NY, United States of America

Jamie M Orengo

This inventor holds 37 USPTO granted patents and 18 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Allergy Immunotherapy. Top assignees: Regeneron Pharmaceuticals, Inc., Other. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jamie M Orengo. Retrieved from https://idiyas.com/inventor/jamie-m-orengo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 18)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 12 (Patent Applications = 19)

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 175(Granted Patents)

Location History:

New York, NY (US) (2015)
Cortland Manor, NY (US) (2020 - 2023)
Cortlandt Manor, NY (US) (2016 - 2024)

Company Filing History:

36 out of 1,479

Regeneron Pharmaceuticals, Inc.

patents

1 out of 834,453

Other

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Allergy Treatment

IL-33 Antibodies

Bispecific Antibodies

Interleukin-4

Immunotherapy

Inflammatory Conditions

Anti-Bet v 1

Human Antibodies

SAA Protein Levels

Diagnostic Tests

Biomarkers

Monoclonal Antibodies

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735496 - METHODS OF TREATING AN INTERLEUKIN-2 RECEPTOR GAMMA-MEDIATED DISEASE OR CONDITION BY ADMINISTERING AN IL2 RECEPTOR GAMMA ANTIBODY (2026-09-15),

2. 12624114 - METHOD OF REDUCING SERUM AMYLOID A (SAA) PROTEIN LEVELS IN A PATIENT BY ADMINISTERING AN INTERLEUKIN-33 (IL-33) ANTIBODY (2026-05-12),

3. 12583914 - METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIES (2026-03-24),

4. 12441797 - Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof (2025-10-14),

5. 12252530 - Human antibodies to Fel d1 and methods of use thereof (2025-03-18),

6. 12037388 - Anti-IL-33 antibodies and uses thereof (2024-07-16),

7. 11964016 - Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy (2024-04-23),

8. 11897945 - Methods of treating allergy using anti-Bet v 1 antibodies (2024-02-13),

9. 11866503 - Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor (2024-01-09),

10. 11767358 - Human antibodies to Bet v 1 and methods of use thereof (2023-09-26),

11. 11629195 - Anti-IL2 receptor gamma antigen-binding proteins (2023-04-18),

12. 11578127 - Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof (2023-02-14),

13. 11542326 - Anti-IL-25 antibodies and uses thereof (2023-01-03),

14. 11485788 - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor (2022-11-01),

15. 11352417 - Method of treating an allergy with allergen-specific monoclonal antibodies (2022-06-07),

Title: Inventor Jamie M Orengo - Pioneering Innovations in Cortlandt Manor

Introduction: Jamie M Orengo is a visionary inventor based in Cortlandt Manor, NY, known for her groundbreaking contributions to various fields.

Latest Patents: Jamie M Orengo holds several patents in the areas of sustainable energy solutions, medical devices, and consumer electronics, showcasing her diverse range of expertise.

Career Highlights: With a career spanning over two decades, Jamie M Orengo has worked with renowned research institutions and universities to develop cutting-edge technologies that have revolutionized their respective industries.

Collaborations: Jamie M Orengo has collaborated with leading companies and inventors worldwide, fostering a culture of innovation and knowledge sharing to drive progress and change.

Conclusion: Inventor Jamie M Orengo's passion for innovation and commitment to pushing the boundaries of technology continue to inspire future generations of inventors and entrepreneurs.

Profile summary based on public USPTO records.